[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention].
|
| Abstract | OBJECTIVE: The purpose of the study is to prospectively investigate the safety and efficacy of anticoagulation with enoxaparin (Clexane) in UA/NQMI patients undergoing PCI procedures. METHODS: UA/NQMI patients received Clexane 1 mg/kg, subcutaneously, q12h for at least 48 hours, the coronary angiography was immediately followed by PCI when indicated and is performed within 8 h after the morning injection. No additional UFH or LMWH was used during or after PCI. Blood samples were taken for further measurement of the anti-Xa activity in 176 patients. RESULTS: 507 UA/NQMI patients were included in the study. 176 patients (93.2%) of the average anti-Xa activity value was > 0.5 IU/ml. During follow-up within 30 days, 3.2% of the patients experienced AMI and 6.7% of the patients recurrent UAP. One patient (0.2%) received revascularization and another died of duodenum perforation. The rate of minor hemorrhage was 4.7% (24 patients). In 30-days follow up, one experienced NQMI and 1 recurrent UA among angiography patients. CONCLUSION: Subcutaneous Enoxaparin given at least for 48 hours before PCI with out additional UFH or LMWH during or after PCI was both safe and effective in high risk UA/NQMI patients.
|
|---|---|
| Authors | Da-yi Hu, Xiu-li Zhao, San-qing Jia, Tian-chang Li, Lei Wang, Hong Zhao, Fan-Long Kong, Bu-xing Chen |
| Journal | Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 42 Issue 2 Pg. 91-3 (Feb 2003) ISSN: 0578-1426 [Print] China |
| PMID | 12783703 (Publication Type: English Abstract, Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!